Novavax sees royalties, reduced expenses on COVID vaccines from Sanofi partnership
Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...
Novavax reports large quarterly revenue declines, rethinks its strategic direction
Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...
Novavax posts Q4 revenue beat despite 80% drop in product sales
Novavax (NASDAQ:NVAX) shares traded marginally higher on Thursday in the premarket after the Gaithersburg, Maryland-based ...
Novavax rising after reporting narrower Q4 loss, revenue beat
Novavax (NVAX) stock moves higher Thursday morning despite releasing mixed fourth quarter results, beating on revenue ...
NVAX Earnings: Novavax Stock Jumps Despite Mixed Q4 Results
Novavax (NVAX) stock jumped today following the release of the vaccine maker’s Q4 2024 earnings report. That follows its diluted earnings per ...
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...
Novavax reports Q4 EPS (51c), consensus (51c)
Reports Q4 revenue $88.3M, consensus $84.38M. “In 2024, we unveiled our new corporate growth strategy, shifting our focus from commercializing ...
Novavax shares up on fourth quarter earnings beat
Shares of Novavax (NASDAQ:NVAX) rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from ...
Novavax Inc. stock outperforms competitors on strong trading day
Shares of Novavax Inc. NVAX advanced 2.09% to $7.32 Wednesday, on what proved to be an all-around mixed trading session for ...
Novavax, Inc.: Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...
Novavax: Q4 Earnings Snapshot
On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 51 cents. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...